Market Closed -
Other stock markets
|
5-day change | 1st Jan Change | ||
0.006 AUD | +20.00% | +20.00% | +20.00% |
Mar. 05 | Invion's Anti-Cancer Drug Logs Postive Preclinical Trial Results | MT |
Feb. 27 | Invion Limited Reports Earnings Results for the Half Year Ended December 31, 2023 | CI |
Sales 2022 | 3.29M 2.14M | Sales 2023 | 4.1M 2.67M | Capitalization | 25.69M 16.71M |
---|---|---|---|---|---|
Net income 2022 | -2M -1.3M | Net income 2023 | -1M -651K | EV / Sales 2022 | 15 x |
Net cash position 2022 | 8.47M 5.51M | Net cash position 2023 | 4.08M 2.66M | EV / Sales 2023 | 5.26 x |
P/E ratio 2022 |
-22.6
x | P/E ratio 2023 |
-13.4
x | Employees | 4 |
Yield 2022 * |
-
| Yield 2023 |
-
| Free-Float | 50.95% |
1 day | +20.00% | ||
1 week | +20.00% | ||
Current month | +20.00% | ||
1 month | +20.00% | ||
6 months | +20.00% | ||
Current year | +20.00% |
Managers | Title | Age | Since |
---|---|---|---|
Thian Chew
CEO | Chief Executive Officer | - | 17-11-30 |
Melanie Leydin
DFI | Director of Finance/CFO | 51 | 20-07-12 |
Brendon Lau
IRC | Investor Relations Contact | - | - |
Members of the board | Title | Age | Since |
---|---|---|---|
Director/Board Member | - | 20-10-21 | |
Thian Chew
CEO | Chief Executive Officer | - | 17-11-30 |
Alan Yamashita
BRD | Director/Board Member | 74 | 19-02-11 |
Date | Price | Change | Volume |
---|---|---|---|
24-03-28 | 0.006 | +20.00% | 5,474,813 |
24-03-27 | 0.005 | 0.00% | 50,000 |
24-03-26 | 0.005 | -9.09% | 2,263 |
24-03-25 | 0.0055 | +10.00% | 254,994 |
24-03-21 | 0.005 | 0.00% | 125,173 |
Delayed Quote Australian S.E., March 28, 2024 at 01:10 am EDT
More quotes1st Jan change | Capi. | |
---|---|---|
+20.00% | 25.15M | |
+9.30% | 46.03B | |
+52.73% | 44.55B | |
+7.15% | 40.8B | |
-8.78% | 28.25B | |
+18.68% | 27.71B | |
-21.92% | 18.82B | |
+14.62% | 13.91B | |
+31.85% | 12.43B | |
+4.47% | 10.81B |